Available Now! 2015 NIH SBIR & STTR Omnibus Grant Solicitation for Small Businesses

The 2015 NIH SBIR and STTR Omnibus Grant Solicitation is now live, and the National Cancer Institute Small Business Innovation Research and Small Business Technology Transfer (NCI SBIR & STTR) Programs have expanded the list of research areas of interest under these funding opportunities.

The Omnibus Solicitations are intended to support small business innovation across a broad spectrum of topic areas. Eligible U.S. small businesses that have the capabilities and expertise to contribute to the research and development missions of the identified topics are encouraged to submit investigator-initiated SBIR & STTR grant applications.

The next application due date is September 8, 2015. We encourage you to start preparing your application now, and are happy to provide feedback on your project. If you’d like to take advantage of this opportunity, please email the NCI SBIR program director listed in your relevant technology area.

*New to SBIR & STTR? Use this interactive infographic to guide you through the NIH application process. 

View the official 2015 SBIR & STTR Omnibus Solicitations:

PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) 
Receipt Dates: September 8, 2015; January 5, 2016; April 5, 2016 

PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Receipt Dates: September 8, 2015; January 5, 2016; April 5, 2016 

View the Application Guide for NIH and Other PHS Agencies for more information on preparing and submitting SBIR & STTR applications. Also, be sure to check that all of your required registrations are complete.

Note: Applicants may now switch between SBIR & STTR Programs. Those who previously were funded under an STTR Phase I award are now eligible to apply for an SBIR Phase II award, and vice versa.

Applications proposing innovative cancer-related technologies with strong commercial potential in a wide range of topic areas are invited through the Omnibus Solicitations. NCI particularly encourages applications in the following current research topics of interest:

  • Development of Low Cost Technologies for Global Health
  • Development of Companion Diagnostics
  • Vaccine Development for Cancer Prevention
  • Novel Technologies to Address “Undruggable” Drug Targets
  • New Technologies to Assess Tissue-Based Markers of Tumor Death and Mitochondrial Stress in Response to Therapy
  • Advances in Chimeric Antigen Receptor (CAR) Vector Engineering to Improve CARs Functionality and Safety
  • Natural Language Processing (NLP) Applications to Electronic Health Records (EHR) to Advance Cancer Prevention and Control
  • Automated Methods for Extraction and Consolidation of Cancer Registry Data
  • Development of Novel Cancer Therapeutics Targeting Epigenetic Alterations
  • Image-Guided Biopsy Platforms for Assessing Tumor Tissue Heterogeneity
  • Cloud Computing Based Sharing, Integration and Analysis of Imaging Data for Cancer Diagnosis, Prognosis and Monitoring
  • New Technologies for Ultrasensitive Molecular Histopathology

Upcoming Opportunities to Meet with NCI SBIR 

Leaders from the NCI SBIR Development Center will be onsite and available at the National SBIR/STTR Conference and BIO 2015 to discuss the SBIR & STTR Programs and initiatives.

Benefits of Applying:

  • SBIR & STTR funding can be a leveraging tool to help attract additional funding from other third-party investors.
  • Awards are not loans; no repayment is required.
  • SBIR & STTR funding is non-dilutive capital (i.e., an award does not impact the company’s stock or shares in any way).
  • Intellectual property rights to technologies developed under these programs are retained by the small business concern.
  • SBIR & STTR awards provide recognition, verification, and visibility.

Questions?
Contact the NCI SBIR Development Center at NCIsbir@mail.nih.gov or visit our Contact Us page for a program director with the relevant area of expertise.

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

Sign up to receive updates about
SBIR & STTR funding opportunities at
sbir.cancer.gov

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: